

GENTA INC DE/  
Form 8-K  
June 30, 2005

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): June 30, 2005

**GENTA INCORPORATED**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**0-19635**

(Commission File Number)

**33-0326866**

(IRS Employer Identification No.)

**Two Connell Drive  
Berkeley Heights, NJ**

(Address of Principal Executive Offices)

**07922**

(Zip Code)

**(908) 286-9800**

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-



**Item 8.01 Other Events.**

On June 30, 2005 Genta Incorporated ( Genta ) issued a press release announcing that the Company has filed a formal Letter of Intent with the European Medicines Agency (EMA) as the initial step for submission of a Marketing Authorization Application (MAA) for Genasense® (oblimersen sodium) Injection, the company's lead anticancer product, for patients with Advanced Melanoma.

On June 30, 2005 Genta issued a press release announcing that the Company has initiated submission of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking marketing approval of Genasense® (oblimersen sodium) Injection, its lead anticancer compound, for patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.

The press releases are attached hereto as Exhibit 99.1 and 99.2 and incorporated herein by reference.

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated June 30, 2005
99.2	Press Release dated June 30, 2005

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENTA INCORPORATED

Date: June 30, 2005

By: /s/ William P. Keane

---

Name: William P. Keane  
Title: Senior Vice President, Chief  
Financial Officer and Corporate  
Secretary

---

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>	<b>Sequentially Numbered Page</b>
99.1	Press Release dated June 30, 2005	
99.2	Press Release dated June 30, 2005	

---